RxDoctor Payments Data

Germone Southall

Psychiatric/Mental Health · Everett, WANPI 1710438163

Payments from drug & device makers

$1,796in general payments, 2019–2025

Across 78 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$648
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$298
  • Otsuka America Pharmaceutical, Inc.$217
  • Neurocrine Biosciences, Inc.$154
  • Vanda Pharmaceuticals Inc.$117
  • Johnson & Johnson$111
  • plus $251 from 3 others

What the payments were for

  • Food & beverage$1,54486%
  • Education$25214%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,796 in reported general payments places this provider in the 85th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$14,623
Medicare patients
38
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate51$160,767
Abilify MaintenaAripiprazole56$149,526
IngrezzaValbenazine Tosylate15$133,192
LybalviOlanzapine/Samidorphan Malate11$18,376
Lurasidone Hcl49$12,669
Clozapine127$11,200
VyvanseLisdexamfetamine Dimesylate20$8,120
Ziprasidone Hcl92$6,320
Divalproex Sodium ErDivalproex Sodium93$3,646
Aripiprazole185$3,616
Quetiapine Fumarate211$3,203
Atomoxetine Hcl47$2,750
Methylphenidate ErMethylphenidate Hcl11$2,301
Prazosin Hcl121$2,196
Olanzapine99$2,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$111$160,76751 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$217$149,52656 claims
Neurocrine Biosciences, Inc.Ingrezza$154$133,19215 claims
Alkermes, Inc.Lybalvi$107$18,37611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 931 psychiatric/mental health providers in Washington.

Other psychiatric/mental health in Everett

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →